Protective Effect of Hainosankyuto, a Traditional Japanese Medicine, on Streptococcus pyogenes Infection in Murine Model by Minami, Masaaki et al.
Protective Effect of Hainosankyuto, a Traditional
Japanese Medicine, on Streptococcus pyogenes Infection
in Murine Model
Masaaki Minami
1*, Mariko Ichikawa
1, Nanako Hata
2, Tadao Hasegawa
1
1Department of Bacteriology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 2Department of Microbiology, Nagoya City University
Hospital, Nagoya, Japan
Abstract
Background: Streptococcus pyogenes (S. pyogenes) causes various serious diseases including necrotizing fasciitis and
streptococcal toxic shock syndrome. One serious problem observed recently with S. pyogenes therapy is attenuation of the
antibiotic effect, especially penicillin treatment failure and macrolide resistance. Hainosankyuto, a traditional Japanese
medicine based on ancient Chinese medicine, has been used for treatment of infectious purulent diseases in Japan. In this
study, we investigated the protective and therapeutic efficacy of Hainosankyuto against S. pyogenes-skin infection.
Methodology/Principal Findings: A broth microdilution method revealed that Hainosankyuto did not show a direct anti-
bacterial effect against S. pyogenes. Force-feeding Hainosankyuto to infected mice for 4 consecutive days increased the
survival rate and reduced the size of local skin lesions compared with mice fed PBS. Although we did not find the significant
recovery of survival rate in Hainosankyuto administration only after S. pyogenes infection, the sizes of ulcer lesion were
significant smaller after Hainosankyuto administration compared with mice fed PBS. No difference was observed in the anti-
bacterial effect of Hainosankyuto between macrolide-susceptible and -resistant strains. Blood bactericidal assay showed
that the survival rate of S. pyogenes using the blood from Hainosankyuto -treated mice was lower than that using the blood
from untreated mice. We also found increased levels of IL-12, IFN-c and a decreased level of TNF-a in the serum of S.
pyogenes-infected mice treated with Hainosankyuto. Mouse peritoneal macrophage from Hainosankyuto-treated mice had
significant phagocytic activity and increased mRNA levels of IL-12, IFN-c and decreased mRNA level of TNF-a compared with
control macrophage.
Conclusions/Significance: Hainosankyuto increased survival rate after S. pyogenes infection and up-regulated both blood
bactericidal activity and macrophage phagocytic activity through modulation of inflammatory cytokines. Our data also
suggest Hainosankyuto may be useful for the treatment of S. pyogenes infection more prophylactically than therapeutically.
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Introduction
The gram-positive bacterium Streptococcus pyogenes (S. pyogenes)i s
the most common agent causing upper respiratory tract and skin
infections [1]. It is also responsible for post-streptococcal diseases,
such as rheumatic fever and glomerulonephritis, in addition to
increasing the incidence of invasive infections such as streptococcal
toxic shock syndrome [1].
One serious problem with S. pyogenes therapy is attenuation of
the antibiotic effect. Despite the fact that S. pyogenes is always
susceptible to penicillin, S. pyogenes infects up to 20% of penicillin-
treated patients, and half of these cases are also clinical failures [2].
In recent years, macrolide- and lincosamide-resistant S. pyogenes
isolates have gradually spread worldwide [3]. Novel anti-microbial
agents other than antibiotics are now being sought.
Traditional herbal medicines are being re-evaluated in the
clinical field because of their relatively few side effects and
suitability for long-term administration compared with synthetic
medicines. Recently, several types of these herbal medicines have
been used clinically for various diseases in Japan [4]. Previous
reports have described the biological actions of herbal medicines
on immune responses in bacterial infection [5]. Herbal medicine
research determining the role of entomopathogenic fungus
Cordyceps sinensis (C. sinensis) in anti-S. pyogenes therapy has been
reported [6]. Production of cytokines, such as interleukin (IL)-12,
interferon (IFN)-c and tumour necrosis factor (TNF)-a , and
upregulation of phagocytic activity by the C. sinensis fraction might
play roles in anti-tumour and anti-bacterial activities.
Hainosankyuto, a traditional herbal Japanese medicine based
on ancient Chinese medicine, has been used for the treatment of
infectious purulent diseases and has been suggested to have various
functions. However, to date Hainosankyuto has not been
investigated for its role in anti-bacterial therapy.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22188In the present study, we evaluated the protective efficacy of
Hainosankyuto against S. pyogenes using a murine skin infection
model. We pre-treated ICR mice with either Hainosankyuto or
PBS and administrated Hainosankyuto or PBS after S. pyogenes
infection for 2 days. We then examined serum cytokine levels,
blood bactericidal activity and mortality in both groups of mice at
each day. Furthermore we also evaluated the therapeutic effect of
Hainosankyuto against S. pyogenes infection and the phagocytic
activity of Hainosankyuto-treated mouse macrophage as the
mechanism of protection.
Results
MIC determination
MIC of Hainosankyuto was above 256 mg/mL. No anti-
bacterial effect of Hainosankyuto against S. pyogenes was observed.
Murine infection model
In the present study, an animal model was used to test whether
Hainosankyuto would provide the host with a protective effect
against S. pyogenes infection. Mice in the control group started to
die on day 2 after inoculation with S. pyogenes 1529, and the
survival rate dropped to 0% after day 4. Mice in the
Hainosankyuto-treated group started to die on day 4 after
inoculation with S. pyogenes 1529, and the survival rate remained
at 80% after day 7 (Figure 1A). In addition, mice in the control
group started to die on day 2 after inoculation with S. pyogenes
D2TY, and the survival rate dropped to 0% after day 4. Mice in
the Hainosankyuto-treated group started to die on day 5 after
inoculation with S. pyogenes D2TY, and the survival rate remained
at 60% after day 7 (Figure 1B). Furthermore, as shown in
Figure 2A, lesion size on day 3 after injection was smaller in the
Hainosankyuto-treated mice injected with S. pyogenes 1529
compared to the control mice (p,0.05). Lesion size in the S.
pyogenes-infected mice was measured, and Figure 2B represented
the significant difference observed in lesion size between
Hainosankyuto-treated and untreated mice (p,0.05).
We next investigated whether Hainosankyuto was useful
therapeutically. Mice in the Hainosankyuto-treated group started
to die on day 2 after inoculation with S. pyogenes 1529, and the
survival rate remained at 33% after day 7 (p=0.0589)(Figure 3A).
In addition, mice in the control group started to die on day 2 after
inoculation with S. pyogenes D2TY, and the survival rate dropped to
0% after day 4. Mice in the Hainosankyuto-treated group started
to die on day 2 after inoculation with S. pyogenes D2TY, and
the survival rate remained at 33% after day 7 (p=0.0569)
(Figure 3B).Although the survival rates of Hainosankyuto-treated
group were higher than those of control group, there was no
significant differences between these 2 groups. However, lesion
size in the S. pyogenes-infected mice was measured, and Figure 4
demonstrated the significant difference observed in lesion size
between Hainosankyuto-treated and untreated mice (p,0.05).
Blood bactericidal assays
To determine whether leukocytes in Hainosankyuto-treated
mice show elevated bactericidal activity, we performed S. pyogenes
killing assays using mouse blood. As shown in Figure 5A, blood
from untreated mice killed approximately 70% of the bacterial
inoculum after a 30-min incubation at 37uC. Similar levels of S.
pyogenes killing were observed in the blood from Balb/C mice (data
not shown). The blood from Hainosankyuto-treated mice killed
approximately 90% of S. pyogenes inoculum after a 30-min
incubation at 37uC. Significant differences were observed in S.
pyogenes 1529 CFU reduction between Hainosankyuto-treated and
untreated mice (p,0.05) (Figure 5A). Significant differences were
observed in S. pyogenes D2TY CFU reduction between Hainosan-
kyuto-treated and untreated mice (p,0.05) (Figure 5B).
Analysis of serum cytokines during infection
The kinetics of appearance of cytokines, such as IL-12, IFN-c
and TNF-a, the serum of infected mice with or without
Hainosankyuto treatment was investigated. Mice in both groups
showed significantly elevated serum IL-12 levels when compared
to those before injection (p,0.05) (Figure 6A). Mice in the
Hainosankyuto-treated group showed a significantly elevated
serum IL-12 and IFN-c level compared to that in control mice
(p,0.05) (Figure 6B). A significant decrease in the TNF-a level
was observed in the Hainosankyuto-treated group at day 1
(p,0.05) (Figure 6C). However, no significant difference was
Figure 1. Prophylactic administration of Hainosankyuto increased the survival rate of S. pyogenes -infected murine models. Three-
week-old ICR mice were force-fed Hainosankyuto ( ) or PBS ( ) for 4 consecutive days (day 21, 0, 1, and 2) and inoculated with 1610
8 CFU of S.
pyogenes 1529 (Figure 1A) and D2TY (Figure 1B) at day 0. Mortality was monitored for 7 days. Survival data were assessed by Kaplan–Meier survival
analysis and tested for significance using the log-rank test.
doi:10.1371/journal.pone.0022188.g001
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days 0, 2 and 3.
Effect of Hainosankyuto on phagocytic activity
We next focussed on macrophage activity from leukocytes
because macrophage plays a major role in phagocytic activity in
murine infection model. To determine whether peritoneal
macrophage from Hainosankyuto-treated mice show elevated
phagocytic activity, we performed phagocytic assays on S. pyogenes.
As shown in Figure 7A, macrophage from untreated mice killed
approximately 60% of the S. pyogenes 1529 inoculum after a 30-min
incubation at 37uC. The macrophage from Hainosankyuto-treated
mice killed more than 99% of S. pyogenes 1529 inoculum after a 30-
min incubation at 37uC. Figure 7B showed that macrophage from
untreated mice killed approximately 90% of the S. pyogenes D2TY
inoculum after a 30-min incubation at 37uC. The macrophage
from Hainosankyuto-treated mice killed more than 99% of S.
pyogenes D2TY inoculum after a 30-min incubation at 37uC.
Significant differences were observed in both S. pyogenes 1529 and
D2TY CFU reduction between Hainosankyuto-treated and
untreated mice (p,0.05) (Figure 7A, Figure 7B).
Cytokine expression of perotineal macrophage in
Hainosankyuto-treated mice
We examined the cytokine expression induced by Hainosan-
kyuto. A group of three ICR mice were force-fed Hainosankyuto
and controls were force-fed PBS. After 24 hour, peritoneal
macrophage was extracted from two groups of mice and three
cytokine expressions were measured by northern blotting analysis
(Figure 8A) and quantitative real time RT-PCR (Figure 8B).
Figure 2. Prophylactic administration of Hainosankyuto prevented the ulcer in S. pyogenes 1529 and D2TY -infected murine
models. Three-week-old ICR mice were subcutaneously inoculated with 1610
8 CFU of S. pyogenes 1529 (Figure 2A). Mice were observed daily for
lesion and necrosis formation. Hainosankyuto decreased the size of ulcerative lesions in S. pyogenes-infected murine model (Figure 2B). Lesion size
(length6width) was measured with length determined as the longest dimension of the lesion. Closed circle and open circle represented
Hainosankyuto -treated and -untreated mouse, respectively. Lesion size data were tested for significance using the t-test. *: p,0.05.
doi:10.1371/journal.pone.0022188.g002
Figure 3. Therapeutical administration of Hainosankyuto tended to increase the survival rate of S. pyogenes -infected murine
models. Three-week-old ICR mice were inoculated with 1610
8 CFU of S. pyogenes 1529 (Figure 3A) and D2TY (Figure 3B). After 24 hour, they were
force-fed Hainosankyuto ( ) or PBS ( ) for 4 consecutive days (day 1, 2, 3, and 4) and. Mortality was monitored for 7 days after infection. Survival data
were assessed by Kaplan–Meier survival analysis and tested for significance using the log-rank test.
doi:10.1371/journal.pone.0022188.g003
Hainosankyuto Protects Mice from S. pyogenes
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expression in mouse macrophage after Hainosankyuto treatment
compared with PBS control. Conversely, the level of TNF-a
mRNA expression was decreasing in mouse macrophage after
Hainosankyuto treatment compared with PBS control.
Discussion
To our knowledge, this is the first study on anti-S. pyogenes
therapy with Hainosankyuto.
After S. pyogenes infection, Hainosankyuto-treated mice showed
increased survival rate, blood bactericidal activity, serum levels of
inflammatory cytokines including IL-12 and IFN-c, macrophage
phagocytic activity and macrophage mRNA levels of inflamma-
tory cytokines including IL-12 and IFN-c. These results suggest
that Hainosankyuto can play an important role in protection
against S. pyogenes.
Our data also potentially postulate that Hainosankyuto may be
useful in treatment of clindamycin-resistant S. pyogenes. Because
Hainosankyuto is not per se an antibiotic and has no anti-bacterial
effect against S. pyogenes, the occurrence of Hainosankyuto-resistant
S. pyogenes in future seems impossible. We speculate that
Hainosankyuto may be efficacious when used against new strains
of antibiotic-resistant S. pyogenes.
We also investigated the effect of Hainosankyuto against other
emm-type S. pyogenes isolates (M4, M12, M28 and M49) and
confirmed that Hainosankyuto had the same inhibitory effect on
those isolates (data not shown). Inhibition of the growth of specific
emm-type isolates and effects of Hainosankyuto may not be related.
Our results imply that Hainosankyuto directly affects the host’s
immune system with regard to S. pyogenes infection.
Hainosankyuto is a traditional Japanese herbal medicine first
prepared by Dr. Todo Yoshimasu, a 17th century Japanese
medical doctor, by combining Hainoto and Hainosan, which are
also traditional Japanese medicines. However, Hainosankyuto is
now popular and widely prescribed for therapy in Japan. Because
neither Hainoto nor Hainosan is easily available commercially, we
chose Hainosankyuto for our study. Although previous studies on
Hainosankyuto have not been found, one report showed the anti-
inflammatory effect of both Hainoto and Hainosan [7]. Both
Figure 4. Therapeutical administration of Hainosankyuto prevented the ulcer in S. pyogenes infected murine model. Three-week-old
ICR mice were subcutaneously inoculated with each strain. Mice were observed daily for lesion and necrosis formation. Lesion size (length6width)
was measured with length determined as the longest dimension of the lesion. Closed circle and open circle represented Hainosankyuto -treated and -
untreated mouse, respectively. Lesion size data were tested for significance using the t-test. *: p,0.05.
doi:10.1371/journal.pone.0022188.g004
Figure 5. Blood bactericidal assay in S. pyogenes-infected murine models. Approximately 1000 CFU of S. pyogenes 1529 (Figure 5A) and
D2TY (Figure 5B) were added to 1 ml of heparinised 3-week-old ICR mouse whole blood and rotated at 37uC. Diluted samples of blood were plated at
the indicated time points to determine the number of CFU. Closed circle and open circle represented Hainosankyuto -treated and -untreated mouse,
respectively. *: p,0.05.
doi:10.1371/journal.pone.0022188.g005
Hainosankyuto Protects Mice from S. pyogenes
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induced vascular permeability and carrageenin-induced hind-paw
oedema; both features of the early exudative stage of inflamma-
tion. Each individual component of Hainosankyuto also shows
anti-inflammatory effect. Platycodin D from Platycodon Root
exert an anti-inflamment effect through the regulation of the NF-k
Figure 6. Time course of serum IL-12, IFN-c and TNF-a levels determined by ELISA in S. pyogenes-infection. Three-week-old ICR mice
were given 1 g/kg body weight of Hainosankyuto or PBS before infection. After S. pyogenes 1529 infection, mice were sacrificed under CO2
anaesthesia at adequate time and blood samples were collected. Serum IL-12 (Figure 6A), IFN-c (Figure 6B), and TNF-a (Figure 6C) were analyzed by
ERISA. Closed circle and open circle represented Hainosankyuto -treated and -untreated mouse, respectively. *: p,0.05.
doi:10.1371/journal.pone.0022188.g006
Figure 7. Mouse peritoneal macrophage phagocyte assay. Three-week-old ICR mouse peritoneal macrophage were prepared and determined
by mixing cells with S. pyogenes 1529 (Figure 7A) or D2TY (Figure 7B) at 37uC. Diluted samples were plated at the indicated time points to determine
the number of CFU. Closed circle and open circle represented Hainosankyuto -treated and -untreated mouse, respectively. *: p,0.05.
doi:10.1371/journal.pone.0022188.g007
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triterpenoid glycoside possessing anti-inflammatory and anti-
allergic activities [9,10]. Paeoniae radix from Peony root has
anti-inflammatory effects in mouse [11]. Ginger root extract,
Immature Orange extract, and Jujube extract have superoxide
diumutase like activities [12]. Although each component has anti-
inflammation effect, this mechanism in detail has been unknown.
Traditional Japanese herbal medicine is generally composed of
several components and the interaction of them may enhance the
effect of drugs. As further investigation from this perspective is
needed, Hainosankyuto may have pronounced anti-inflammatory
effects.
We tried to clarify the mechanism of this protective effect of
Hainosankyuto. Our data suggest that the protection provided was
not due to any direct anti-bacterial effect of Hainosankyuto.
Augmentation of blood bactericidal activity might help the host
eliminate bacteria at the infection site, and innate immunity is
important in this elimination. IL-12-induced IFN-c expression
provided protection against S. pyogenes infection in a murine model
by enhancing innate immunity [13,14]. TNF-a suppression also
plays a crucial protective role in severe S. pyogenes infection [15].
Not only blood bactericidal activity but also mouse peritoneal
macrophage phagocytic activity, was enhanced in the Hainosan-
kyuto-treated group. Hainosankyuto-treated mice showed signif-
icantly higher IL-12 and IFN-c levels and a significantly lower
TNF-a level than untreated mice. Taken together, we suggested
that Hainosankyuto-induced cytokine production augments bac-
tericidal activity including phagocytic activity which in turn causes
bacterial elimination.
In addition, we next tried to clarify whether Hainosankyuto
would provide protection if given only after bacterial infection.
Although we did not find the significant recovery of survival rate in
direct Hainosankyuto administration only after S. pyogenes
infection, our results showed that the sizes of ulcer lesion were
significant smaller after Hainosankyuto administration compared
to PBS administration. Hainosankyuto may be useful for therapy
of local lesion after S. pyogenes infection. Further clinical study
involving human subjects about S. pyogenes therapy using
Hainosankyuto is desired. Also whether a similar effect occurs in
other bacterial infections warrants further investigation.
In summary, Hainosankyuto was more effective in preventing
S.pyogenes infection than in administration only after S. pyogenes
infection. We suggest Hainosankyuto as a candidate for novel anti-
S. pyogenes therapy.
Materials and Methods
Bacterial strains
S. pyogenes 1529 and D2TY were clinical isolates from severe
invasive disease in Japan [16,17]. S. pyogenes D2TY in particular
has a macrolide-resistant gene, ermB. A fresh colony was inoculated
overnight on blood agar (Nihon Becton Dickinson, Tokyo, Japan)
and cultured for 12 hour at 37uC. The bacteria were harvested by
centrifugation and re-suspended in sterile PBS. Bacterial density
was determined by measuring absorbance at 660 nm (A660). The
bacterial suspension was then diluted with PBS to 10
9 CFU
(colony forming unit)/mL using a standard growth curve to relate
measured A660 to bacterial concentration.
Compound
Hainosankyuto was provided as a generous gift from the
Tsumura Company Limited (Tokyo, Japan) (Table 1), and it was
suspended in distilled water to prepare the stock solution at a
concentration of 0.1 g/mL.
Figure 8. Levels of cytokine mRNA in mouse peritoneal macrophage with Hainosankyuto treatment. Three-week-old ICR mice were
force-fed Hainosankyuto for 1 day. Mouse peritoneal macrophage was prepared as a single-cell suspension. Then total RNA was extracted and IL-12,
IFN-c, and TNF-a expression was detected using northern blotting analysis (Figure 8A) and quantitative real time RT-PCR (Figure 8B), with HPRT as the
internal control.
doi:10.1371/journal.pone.0022188.g008
Table 1. Crude composition of hainosankyuto extract.
Crude drug Composition (g) Yield (g)
Platycodon Root 4.0 4.5
Glycyrrhiza 3.0
Immature Orange 3.0
Peony Root 3.0
Jujube 3.0
Ginger 1.0
doi:10.1371/journal.pone.0022188.t001
Hainosankyuto Protects Mice from S. pyogenes
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MIC of Hainosankyuto was determined using the micro-
dilution method in accordance with the guidelines of the Clinical
and Laboratory Standards Institute [18]. MIC was defined as the
lowest concentration showing no visible growth after 24 hour of
incubation at 35uC compared to the control.
Murine model of invasive skin and soft tissue infection
The ability of S. pyogenes to cause local skin lesions in mice after
subcutaneous inoculation was assessed using a procedure
described elsewhere [19]. In brief, S. pyogenes was harvested after
16-hour growth on brain heart infusion agar (Eiken Chemical
Co., Tokyo, Japan) containing 0.3% yeast extract (BHY agar)
with appropriate antibiotics mixed in 1 mL of PBS and then
centrifuged at 2000 g for 2 min. The pellets were diluted in
100 ml PBS to 1610
8 CFU and then injected under the skin
surface of inbred 3-week-old female Slc:ICR mice (Japan SLC,
Inc., Shizuoka, Japan) using a 25-gauge needle. The number of
CFU injected was verified for each experiment by plating the
bacteria on BHY agar and counting CFU. Mice were observed
daily for lesion and necrosis formation. Lesion sizes
(length6width) were measured with length determined as the
longest dimension of the lesion. In the Hainosankyuto-treated
group, mice were force-fed Hainosankyuto (0.1 mL/10 g body
weight (bw)) on days 21, 0, 1 and 2 after S. pyogenes inoculation.
Mice in the control group were given an equal volume of PBS
and were infected using the same method. We also performed
another protocol to clarify the effects of Hainosankyuto in
animals developing signs. In the Hainosankyuto-treated group,
mice were force-fed Hainosankyuto (0.1 mL/10 g body weight
(bw)) on days 1, 2, 3 and 4 after S. pyogenes inoculation. We
evaluated the mortality and the size of necrosis using same
methods as prophylactic assay.
Blood bactericidal assay
Blood bactericidal assays were performed as an evaluation of
whole blood bactericidal effect with some modification [19]. In the
Hainosankyuto-treated group, mice were force-fed Hainosankyuto
(0.1 mL/10 g body weight (bw)) on 1 day before collection. Mice
in the control group were given an equal volume of PBS.
Heparinised blood was collected from Hainosankyuto-treated and
untreated mice not infected with S. pyogenes. Blood bactericidal
assays were performed as follows; approximately 1000 CFU of
strain was added to 1 mL of heparinized ICR mice whole blood.
The samples were incubated at 37uC on a rotator. Aliquots were
removed and plated on BHY agar to determine the number of
CFU after 0, 30 and 60 min. Data were expressed as bacterial
CFU counts at each times.
Analysis of serum cytokines during infection
We determined the levels of serum cytokines, such as IL-12,
IFN-c and TNF-a during the course of infection in S. pyogenes-
infected ICR mice treated with Hainosankyuto. Blood from both
infected and treated/infected groups was collected under anaes-
thesia at 1 and 3 days after infection. Each blood sample was
centrifuged, and the resultant serum was stored at 280uC until the
day of assay. IL-12, IFN-c and TNF-a levels were determined by
sandwich ELISA (Quantikine, R&D Systems Inc., MN, USA). For
the assay, combinations of capture and biotinylated mAb were
used as recommended by the manufacturer. Cytokine levels were
calculated using standard murine recombinant cytokine curves run
on the same immunoplate.
Macrophage cells
In the Hainosankyuto-treated group, mice were force-fed
Hainosankyuto (0.1 mL/10 g body weight (bw)) on 1 day before
peritoneal lavage. Mice in the control group were given an equal
volume of PBS. Mouse peritoneal macrophage cells were
harvested by lavage with 6 ml of cold Hank’s balanced salt
solution (Wako pure chemical industry, Osaka, Japan) from the
peritoneal cavities. The cells were washed twice and suspended in
culture medium to give 10
6 cells/mL. Five hundred mL of the cell
suspension was dispensed into 1.5 mL tube and incubated for
2 hour at 37uCi n5 %C O 2. The culture medium was removed
gently by aspiration and changed to fresh culture medium. For cell
culture, RPMI-1640 (Wako pure chemical industry) supplemented
with 5% inactivated fetal bovine serum was used. All cells were
suspended in the culture medium, plated onto 24-well culture plate
at dose of 6610
5 cells per well (final volume, 0.6 mL) and cultured
in a humidified chamber at 37uC with 5% CO2 and 95% air. The
5 hour culture was washed three times with Hanks’ balanced salt
solution to remove nonadherent cells and the adherent cells only
were used as the macrophage culture.
Macrophage phagocyte assay
Mouse peritoneal macrophage were mixed with S. pyogenes and
incubated for 1 hour with shaking at 37uC. Briefly, macrophage
phagocyte assays were performed using polypropylene tubes
containing 100 ml mouse macrophage (2610
5 cells) and 100 mL
S. pyogenes to yield a final concentration of 10
5 CFU/mL. S. pyogenes
was opsonized with mouse serum for 30 min before mixing. The
samples were incubated at 37uC on a rotator, and aliquots were
removed for quantitative and plated on BHY agar to determine
the number of CFU after 0, 30 and 60 min. Data were expressed
as bacterial CFU counts at each times.
Northern blotting analysis
Total RNA was extracted using by QIAGEN RNA extraction
kit (QIAGEN, Hilden, Germany) according to the manufacture’s
instructions. Approximately five mg of each total RNA preparation
was electrophoresed on 1% agarose gels containing 1.1 M
formaldehyde. The RNA was transferred to a Hybond-N+
membrane (GE Healthcare, Waukesha, WI). For DNA probes,
primers used were: HPRT, 59-GTTGGATACAGGCCAGAC-
TTTGTTG-39 and 59-GAGGGTAGGCTGGCCTATAGGCT;
IL12, ATGGCCATGTGGGAGCTGGAGAAAG and 59-GTG-
GAGCAGCAGATGTGAGTGGCT-39; INF-c,5 9-AACGCTA-
CACACTGCATCT-39 and 59-TGCTCATTGTAATGCTT-
GG-39; TNF-a,5 9-GTTCTATGGCCCAGACCCTCACA-39
[20]. The mRNA was detected with 32P-labeled HPRT, IL12,
INF-c, and TNF-a DNAs (random primer DNA labeling kit,
version 2; Takara Bio Co. Ohtsu, Japan). The membranes were
then autoradiographed and analyzed at room temperature with a
bioimaging analyzer (BAS-1800II; Fujifilm, Tokyo, Japan).
Triplicate assays were performed with RNA from at least three
independent cultures.
Quantitative real time RT-PCR
Five mg of RNA was reverse transcribed using SuperScript first-
strand synthesis system (Invitrogen Co., Carlsbad, CA, USA). The
cDNA samples were then subjected to PCR analysis. Primers used
were described as above (Northen blotting analysis section). To
quantitate mRNA, a real-time RT-PCR was performed by using
the GeneAmp 7900 sequence detection system with SYBR green
reagent (Life technologies Corp., Carlsbad, CA). Samples were
subjected to 40 cycles of amplification consisting of 95uC for 15 s
Hainosankyuto Protects Mice from S. pyogenes
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instructions. Each assay was normalized to HPRT mRNA.
Statistical analysis
Comparison between groups regarding blood bactericidal and
cytokine assays were made using the t-test. Survival data were
assessed by Kaplan–Meier survival analysis and tested for
significance using the log-rank test. Lesion size data were also
tested for significance using the unpaired two-tailed t-test. A
p,0.05 were considered significant.
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